AstraZeneca Paludrine tablets

AstraZeneca Paludrine tablets

Simon Dawson/Bloomberg

AstraZeneca, in an attempt to convince its investors that they’re better off not taking the cash-and-stock offer, made a prediction this week that revenue will climb 75 percent by 2023.